@StockInvestUS
YouTube
Avg. Quality
70
Success Rate
43.15
Analysis
1189
Correct
513
Fail
636
Pending
37
Ineffective
0
Total Quality
Score
If You Had Traded on This Analysis…
Correct
PATH
Short Entry
14.7850
2026-01-16
04:25 UTC
Target
14.5500
In 10 Hours
Fail
15.4300
Risk/Reward
1 : 0
Turn Signals into Profit
Join Tahlil Plus Pro to unlock full performance history, live alerts, and AI-backed risk tools.
Start Free
Final PnL
1.59%
P/L: —
Turn Signals into Profit
Join Tahlil Plus Pro to unlock full performance history, live alerts, and AI-backed risk tools.
Start Free
UiPath Inc. is currently designated as a 'Sell Candidate' with a score of -2.088, reflecting a bearish short-term outlook. The stock recorded a 7.39% decline over three days, translating to an average daily loss of 2.46%. On Thursday, January 15, 2026, the closing price was $14.79, down 3.77%, marking the third consecutive daily decrease. An increase of 2 million shares in trading volume during this price decline suggests heightened risk. Technical analysis reveals numerous negative signals, including sell signals from both short-term and long-term Moving Averages and the MACD. Resistance levels are identified at $15.43 (Fibonacci) and $15.93 (Accumulated Volume), with a support level at $14.55. A breach above resistance is expected to trigger buy signals, contradicting the prevailing bearish forecast. Conversely, failure to hold the $14.55 support level could lead to further price depreciation. The stock is 25.45% below its 52-week high of $19.84. Insider trading data indicates a negative 'Insider Power' of -20.865, reflecting a significant imbalance of insider selling over buying in the last 100 transactions. While long-term fundamentals show accelerating revenue growth and a path to GAAP profitability by fiscal 2026, near-term market volatility and insider exits contribute to a cautious sentiment. The current price-to-earnings ratio is 34.70. For Friday, January 16, 2026, the stock is projected to open higher by approximately $0.207, starting at $15.00, despite the overarching negative evaluation. No specific stop-loss has been established.